AstraZeneca to Invest $15 Billion in China by 2030

Landmark investment will expand the company's capabilities in innovative medicines and manufacturing

Jan. 29, 2026 at 4:15am

Got story updates? Submit your updates here. ›

AstraZeneca announced a $15 billion investment in China through 2030 to expand its medicines manufacturing and R&D capabilities. The investment will leverage China's scientific excellence, advanced manufacturing, and healthcare ecosystem collaborations to deliver cutting-edge treatments to patients across China and globally.

Why it matters

This landmark investment by AstraZeneca in China signals the country's growing importance as a hub for pharmaceutical innovation and manufacturing. It will strengthen China-UK collaboration in healthcare and benefit the life sciences ecosystems of both countries.

The details

The investment will significantly enhance AstraZeneca's cell therapy and radioconjugates capabilities, driving its pipeline of treatments for cancer, hematological conditions, and autoimmune diseases. It will also expand the company's existing manufacturing facilities in China and establish new sites, growing its workforce in the country beyond 20,000 and creating thousands of additional jobs across the healthcare ecosystem.

  • AstraZeneca announced the $15 billion investment on January 29, 2026.

The players

Keir Starmer

The UK Prime Minister, who said the investment will help the British manufacturer continue to grow, supporting thousands of UK jobs.

Pascal Soriot

The Chief Executive Officer of AstraZeneca, who said the investment will strengthen the company's contribution to China's high-quality development and bring next-generation treatments to patients.

AstraZeneca

A global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines.

Got photos? Submit your photos here. ›

What they’re saying

“Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements. AstraZeneca's expansion and leadership in China will help the British manufacturer continue to grow - supporting thousands of UK jobs. The multi-billion pound investment announced today from AstraZeneca, alongside partnerships from some of our country's leading universities, furthers research and development in the UK which is helping to power our world class life sciences sector.”

— Keir Starmer, UK Prime Minister

“Today's landmark investment of $15 billion begins an exciting next chapter for AstraZeneca in China, which has become a critical contributor to scientific innovation, advanced manufacturing, and global public health. By expanding our capabilities in breakthrough treatments like cell therapy and radioconjugates, we will strengthen our contribution to China's high-quality development and, most importantly, bring next-generation modalities to patients.”

— Pascal Soriot, Chief Executive Officer, AstraZeneca

What’s next

The investment will support the delivery of China's 'Common Health' agenda, to expand prevention, early detection, and access to innovative medicines for underserved communities.

The takeaway

AstraZeneca's landmark $15 billion investment in China underscores the country's growing importance as a hub for pharmaceutical innovation and manufacturing, and will strengthen the collaboration between the UK and China's life sciences ecosystems.